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Abstract
Background: The current standard treatment, at least in Europe, for patients with primarily resectable tumors,
consists of surgery followed by adjuvant chemotherapy. But even in this prognostic favourable group, long term
survival is disappointing because of high local and distant failure rates. Postoperative chemoradiation has shown
improved local control and overalls survival compared to surgery alone but the value of additional radiation has
been questioned in case of adjuvant chemotherapy. However, there remains a strong rationale for the addition of
radiation therapy considering the high rates of microscopically incomplete resections after surgery. As
postoperative administration of radiation therapy has some general disadvantages, neoadjuvant and intraoperative
approaches theoretically offer benefits in terms of dose escalation, reduction of toxicity and patients comfort
especially if hypofractionated regimens with highly conformal techniques like intensity-modulated radiation therapy
are considered.
Methods/Design: The NEOPANC trial is a prospective, one armed, single center phase I/II study investigating a
combination of neoadjuvant short course intensity-modulated radiation therapy (5 × 5 Gy) in combination with
surgery and intraoperative radiation therapy (15 Gy), followed by adjuvant chemotherapy according to the
german treatment guidelines, in patients with primarily resectable pancreatic cancer. The aim of accrual is 46
patients.
Discussion: The primary objectives of the NEOPANC trial are to evaluate the general feasibility of this approach
and the local recurrence rate after one year. Secondary endpoints are progression-free survival, overall survival,
acute and late toxicity, postoperative morbidity and mortality and quality of life.
Trial registration: NCT01372735.
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Pancreatic cancer is the fourth leading cause of cancer
death in both men and women [1,2]. The only way to
cure is complete surgical resection, but only about 15-
20% of the patients are amendable to primary surgery at
presentation [3]. Even in this prognostic favourable
group, five-year survival rates are below 25% [4]. On the
one hand, these patients are at high risk for local recur-
rence, which develops in up to 50% despite aggressive
surgical approaches [5,6] and built the rationale for an
additive use of radiation therapy. Especially in the US,
postoperative chemoradiation has emerged as the stan-
dard of care after a survival benefit had been shown
compared to surgery alone in the GITSG trial [7]. On
the other hand, these patients are also at high risk for
distant metastases, which built the rationale for an addi-
tive use of systemic therapy. In most European coun-
tries, postoperative chemotherapy has emerged as the
standard of care because of its survival benefit compared
to surgery alone [8,9] and the absence of well-designed
randomised trials showing a benefit for adjuvant che-
moradiation vs chemotherapy alone. However, the low
acceptance of chemoradiation as an adjunct to surgery
in Europe, may be caused by some disadvantages
because of its postoperative rather than its principle use.
Postoperative administration of radiation therapy dose
not only cause a delay in dose-intense chemotherapy,
but has several limitations in terms of target volume
definition as well as in total dose because of the low tol-
erance of surrounding organs at risk [10].
These limitations have lead to preoperative radiation
strategies in several other diseases, for example in rectal
cancer [11,12], which offer several advantages, for exam-
ple an easier target volume definition, less toxicity to
adjacent organs at risk because of their displacement by
the tumor itself and the possible use of smaller safety
margins [13], devitalisation of tumor cells prior to sur-
gery [14], improved response due to better tissue oxyge-
nation [13] and the avoidance of treatment delay due to
postoperative complications [15,16]. In pancreatic can-
cer, such neoadjuvant strategies have mainly been inves-
tigated in locally advanced cases because of their
potential to down size tumor masses and resulted in
secondary resectability in 30-80% of the patients [17],
but their principle advantages compared to postopera-
tive approaches have also been confirmed in resectable
cases [18]. However, the delay of surgery and che-
motherapy by long course radiation therapy schedules
seem to be a matter of concern. Hypofractionated short
course radiation regimens can overcome this limitation
and have shown equal benefit in terms of local control
with less acute side effects for example in rectal cancer
[12,19,20]. One of the most common short course
radiation regimens in rectal cancer uses 5 fractions of 5
Gy each during one week [12]. Using the linear-quadra-
tic model, the biological effect of this regimen corre-
sponds to about 40 Gy in conventional fractionation
[21], which is less than the commonly used 50-54 Gy
with long term schedules. However, given the high rate
of microscopically incomplete resections in pancreatic
cancer (up to 75%) [4,22-24], external beam radiation
therapy approaches alone seem to be insufficient regard-
less of their fractionation schedule because of their gen-
eral dose limitations caused by the low tolerance of the
surrounding organs at risk like small bowel and kidneys
[25].
To overcome this general limitation, an intraoperative
electron boost (IORT) has been introduced successful
into the treatment of several malignancies arising in the
abdominal cavity. IORT means the application of a high
single dose (usually 10 to 20 Gy) under visual control
during a surgical intervention exploiting the possibility
to displace organs at risk with low radiation tolerance
completely from the radiation fields. Considering the
increased biological effectiveness of a high single dose
[26], total doses which are equivalent to 60-70 Gy in
conventional fractionation can be achieved using an
IORT boost in combination with moderate doses of
external beam radiation therapy [27]. The combination
of IORT and EBRT has been shown to improve local
control compared to EBRT alone for example in retro-
peritoneal sarcoma as proven by a randomized con-
trolled trial [28]. In resectable pancreatic cancer
patients, a significant improvement in local control and
even in overall survival was found with IORT compared
to surgery alone in a retrospective analysis by Reni et al.
[29], and a recently published pooled analysis of several
european IORT centers concluded that combination of
IORT with neoadjuvant EBRT is superior to a combina-
tion with postoperative EBRT [25]. Therefore the aim of
this study is to investigate a neoadjuvant short course
EBRT schedule (5 × 5 Gy), followed by surgery with an
intraoperative electron boost (15 Gy) in patients with
resectable pancreatic cancer, in order to reduce the local
recurrence rate. The potential advantage of a neoadju-
vant regimen compared to a postoperative schedule con-
sists of a simplified target volume definition, improved
sparing of dose to surrounding organs at risk and the
devitalisation of tumor cells prior to surgery. The poten-
tial advantage of a short course regimen compared to a
long course schedule consists of a shorter delay of surgi-
cal and dose-intense systemic therapy and a decreased
risk of acute radiation side effects and surgical morbidity
due the short latency between irradiation and surgery.
The combination with an intraoperative boost yields
total doses which should be able to control even
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cent organs at risk. The clinical trial will further be
accompanied by the examination of blood and tissue
samples before, during and after the radiation treatment
using gene expression profiling in order to identify pos-
sible predictive factors for treatment response and
outcome.
Methods/Design
Study design
The purpose of the study is to investigate the value of a
neoadjuvant hypofractionated short course radiation
therapy schedule followed by immediate surgery and an
intraoperative boost to the tumor bed in patients with
primarily resectable pancreatic cancer. The trial will be
performed as a single-center one-armed phase I/II study.
Patient selection and inlcusion/exclusion criteria
46 patients fulfilling the inclusion criteria listed below
should be enrolled in this trial. Only patients meeting
all of the inclusion criteria and missing all of the exclu-
sion criteria (see Table 1) will be considered for admis-
sion to the trial.
Trial organization
NEOPANC has been designed by the Departments of
Radiation Oncology and Biostatistics at the German
Cancer Research Center (DKFZ) in cooperation with the
European Pancreas Center and the Departments of Gen-
eral Surgery and Radiation Oncology at the University of
Heidelberg. It will be carried out by the Department of
Radiation Oncology at the German Cancer Research
Center (DKFZ) together with the European Pancreas
Center and the Departments of Radiation Oncology and
General Surgery at the University of Heidelberg. The
trial is an investigator initiated trial.
Coordination
The trial is coordinated by the Department of Radiation
Oncology at the German Cancer Research Center
(DKFZ) and the European Pancreas Center at the Uni-
versity of Heidelberg in cooperation with the Depart-
ments of General Surgery and Radiation Oncology of
the University of Heidelberg. The Department of Radia-
tion Oncology at the German Cancer Research Center
(DKFZ) and the European Pancreas Center at the Uni-
versity of Heidelberg are responsible for overall trial
management, database management, quality assurance,
reporting and for the scientific program of all trial
related meetings. The trial has been registered at Clini-
calTrials.gov [NCT 01372735].
Investigators
Patients will be recruited by the European Pancreas
Center and the Department of General Surgery at the
University of Heidelberg. All investigators are experi-
enced oncologists from the field of radiation oncology
or surgery cooperating in this trial.
Ethical and legal considerations
The study protocol was approved by the independent
ethics committee of the medical faculty at the University
of Heidelberg and the German Federal Authorities for
Radiation Protection (Bundesamt fuer Strahlenschutz).
Table 1 Inclusion and Exclusion Criteria
Inclusion criteria Exclusion criteria
￿ written informed consent
￿ histologically confirmed, primary pancreatic cancer
of the pancreatic head
￿ judged as gross completely resectable
￿ absence of lymph node metastases at the splenic
hilum or along the pancreatic tail
￿ no evidence of distant metastases
￿ age > 50 years
￿ Karnofsky performance score ≥ 70%
￿ adequate bone marrow function (neutrophils >
2000/μl, platelets > 100000/μl)
￿ adequate renal function (Creatinine < 1.5 mg/dl)
adequate liver function
￿ missing written informed consent
￿ missing histological conformation of pancreatic cancer
￿ judged as gross incomplete or not resectable
￿ pancreatic cancer located in the pancreatic corpus or tail
￿ recurrent pancreatic cancer
￿ incomplete staging
￿ presence of lymph node metastases along the pancreatic tail or splenic hilum
￿ presence of distant metastases
￿ prior radiation therapy to the upper abdominal region
￿ neoadjuvant chemotherapy or immunotherapy
￿ participation in another clinical interventional study
￿ age ≤ 50 years
￿ other previous or active malignancy (excluding basal cell carcinoma, carcinoma in situ of
the cervix)
￿ Karnofsky performance score < 70%
￿ inadequate bone marrow function
￿ inadequate renal or liver function
￿ any other disease or situation, which generally prohibits the use of major surgery or
radiation therapy according to the judgement of a surgeon or radiation oncologist
￿ inability to participate in regular follow up
￿ pregnancy, inability or incompliance for adequate contraception
￿ missing ability to give informed consent
legal custody
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and regulatory requirements. The study complies with
the Declaration of Helsinki 2008, the principles of Good
clinical practice (GCP) and the German Federal Data
Protection Act. Written informed consent will be
obtained from each patient before inclusion into the
trial after nature, scope and possible consequences of
participation in the trial have been explained by a
physician.
Study objectives and endpoints
The primary objective is to evaluate the local recurrence
rate after 1 year. Secondary objectives are general feasi-
bility of this approach, acute and late toxicity, periopera-
tive morbidity and mortality, progression-free survival,
overall survival, quality of life and the identification of
prognostic biomarkers.
Pretreatment evaluation
Initial work up consists of clinical examination, labora-
tory tests including tumor markers, CT or MR-imaging
of the abdominal cavity, thoracic CT, assessment of
baseline quality of life, evaluation of general ability to
receive major surgery and evaluation of resectability.
Treatment assignment and schedule
All patients will be assigned to the same treatment regi-
men in this trial (see Figure 1). Patients who fulfill the
inclusion criteria after pretreatment evaluation and gave
written informed consent will receive immobilization
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Figure 1 Flow Chart of the NEOPANC Study. IMRT: intensity-modulated radiation therapy, IORT: Intraoperative Radiation Therapy, Gy: Gray, Fx:
Fractions.
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short course radiation therapy within 1 week after regis-
tration at the Department of Radiation Oncology, Ger-
man Cancer Research Center. Neoadjuvant intensity-
modulated short course irradiation will start within 1
week after treatment planning and will be carried out in
5 fractions during one week using an image guided
intensity-modulated radiation technique up to a total
dose of 25 Gy. Surgical resection of the tumor including
intraoperative radiation therapy (IORT) with a single
dose of 15 Gy will be carried out within 1 week after
the end of neoadjuvant irradiation at the department of
surgery in cooperation with the department of Radiation
Oncology at the University of Heidelberg. After post-
operative recovery, all patients will be assigned to regu-
lar follow up visits either at the department of Radiation
Oncology at the German Cancer research center or at
the department of Surgery at the University of Heidel-
berg. Also all patients will be scheduled to receive post-
operative systemic therapy according to the german
pancreatic cancer treatment guidelines [30], although
systemic treatment is not an inherent part of the study
protocol and will be given independently from study
participation.
Neoadjuvant short course radiation therapy
For external beam radiation therapy, patients will be
immobilized using an individual vacuum pillow. For
treatment planning, contrast enhanced CT as well as
MR imaging will be performed for optimal target defini-
tion. Organs at risk like small bowel, stomach, liver, kid-
neys and spinal cord will be contoured. The CTV
includes the gross tumor volume and the regional
lymph node areas. A safety margin of 1 cm will be
added to obtain the PTV. The margin maybe reduced
with respect to anatomical borders or organs at risk at
the discretion of the investigator. The prescribed dose
to the PTV is 25 Gy in 5 fractions with the 95% isodose
surrounding the PTV contour. The dose constraint to
the spinal cord is 15 Gy in maximum. The median dose
to kidneys and liver should be below 7 and 10 Gy,
respectively. Only one third of the kidney is allowed to
g e tm o r et h a n1 5G y .T h em i n i m u ma n dm a x i m u m
doses inside the PTV should not exceed the range of
95% to 107%. Inverse treatment planning will be done
using the planning systems at the Department of Radia-
tion Oncology of the German Cancer Research Center.
Treatment will be performed using step-and-shoot
intensity modulated radiation therapy with 5 to 9 copla-
nar 6 MV-beams after stereotactic target point localisa-
tion. Daily setup correction will be done using an
image-guided approach with an In-Room-CT on rails
(Siemens Somatom Emotion, Siemens, Erlangen,
Germany) by comparison of the current CT with the
planning CT prior to every fraction.
Surgery and intraoperative radiation therapy
Surgery will be performed within one week after com-
pletion of neoadjuvant irradiation at the Department of
General Surgery of the University of Heidelberg. A cura-
tive resection either as pancreatic head resection or total
pancreatectomy is attempted. An additional intraopera-
tive electron boost will be performed using a dedicated
linear accelerator inside the operation theatre (Siemens
M e v a t r o n ,S i e m e n s ,C o n c o r d ,U S A ) .T h et a r g e tv o l u m e
of the intraoperative boost includes the tumor bed, the
celiac and superior mesenteric origins, the mesenteric
root, the portal vein and the adjacent paracaval and
paraaortic lymph node regions. Therefore an applicator
of appropriate size will be placed inside the abdominal
cavity and attached to the table by a radiation oncologist
in correspondence with the treating surgeon. Unin-
volved radiosensitive tissues will be removed from the
treatment area or covered by lead shielding. After align-
ment with the accelerator, the target volume will be
irradiated with a single dose of 15 Gy, prescribed to the
90% isodose. The electron energy will be selected
according to the tissue depth that has to be covered in
order to encompass the target volume with the 90%
isodose.
Follow up
Regular follow up visits will start at discharge of the
hospital stay after surgery and will take place every 3
months after surgery for the first 3 years and every 6
months for two further years. They will include clinical
examination, CT or MR-imaging of the abdominal cav-
ity, laboratory examinations including Ca 19-9 measure-
ments, assessment of acute/late toxicity and quality of
life as well as any other necessary test or examination in
case of clinical or biochemical suspicion of local recur-
rence or distant metastases (at least CT or MR-imaging
of lungs and brain and bone scan). All patients will be
followed for 5 years or until death or end of study parti-
cipation due to other reasons.
Assessment of efficiacy
Local recurrence rate after 1 year is the primary end-
point of the trial. It will be assessed by repeated CT or
MR-imaging during regular follow up. In case of a single
suspicious locoregional lesion, histological confirmation
will be attempted. Otherwise, new lesions with typical
radiological signs of a local recurrence in combination
with or without a rise of tumormarkers (depending on
the tumormarker status before start of treatment) will
be counted as local recurrence. In case of missing
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therapy, a local disease progression according to
RECIST criteria will be counted as a local recurrence.
Progression free survival is a secondary endpoint of
the study. Progression-free survival will be counted from
t h ef i r s td a yo fr a d i a t i o nt h e r a p yu n t i lt h ed a t eo ft h e
first event either locally or distantly or death due to any
cause. Patients alive without progressive disease at the
time of data analysis will be censored at the time of the
most recent follow up. In case of lesions suspicious for
distant metastases, histological or cytological confirma-
tion is attempted. Otherwise, new lesions with typical
radiological signs of distant metastases with or without
a rise of tumormarkers (depending on the tumormarker
status before start of treatment) will be counted as
events. Notably, the sole rise of tumormarkers without
any clinical or radiological evidence for a local or distant
progression or the sole occurrence of effusions like
ascites without a cytological confirmation will not be
counted as an event, especially during adjuvant systemic
therapy.
Overall survival is a secondary endpoint of the study.
The duration of survival is the time interval from the
first day of radiation treatment until death of any cause.
Patients not reported dead or lost to follow-up will be
censored at the date of the last follow-up examination.
Assessment of toxicity
Acute radiation toxicity will be assessed according to
Common Terminology Criteria for Adverse Events Ver-
sion 3.0 during the time period from the first day of
neoadjuvant radiation treatment until 3 months after
surgery or until start of adjuvant systemic treatment.
Late radiation toxicity will be scored according to
RTOG criteria. Toxicity will regularly be evaluated by
clinical and laboratory examinations after the first, third
and fifth fraction of neoadjuvant radiation therapy. Post-
operative morbidity will be assessed at discharge of the
hospital stay and 3 months after surgery and late toxi-
city will be scored during every further regular follow
up visit.
Assessment of quality of life
Measurement of quality of life is one of the secondary
objectives of the trial. Two questionnaires are used in
this study to assess QoL. EORTC QLQ-C30 is a general
measure of quality of life in cancer patients. It incorpo-
rates nine multi-item scales: five functional scales (phy-
sical, role, cognitive, emotional, social); three symptom
scales (fatigue, pain, nausea and vomiting); and a global
health scale [31]. Specific symptoms (dyspnea, insomnia,
anorexia, constipation, diarrhea, financial impact) are
measured as six single items. This instrument has been
used in a variety of trials so far and showed a good
internal consistency and good re-test reliability [32].
The second questionnaire is a specific pancreatic mod-
ule (QLQ-PAN26) [33], which has been designed to be
used together with the general measure to assess dis-
ease-specific symptoms in patients with pancreatic
cancer.
Safety and discontinuation of treatment
Toxicities are classified by type, grade, duration, onset
and relationship to radiation treatment. Study participa-
tion will be terminated in an individual patient, if the
patient suffers from a grade 4 toxicity related to radia-
tion treatment or if the patient withdraws consent to
further participation. The trial itself will be aborted if a
patient suffers from a grade 5 toxicity related to radia-
tion therapy or if more than 2 of the first 10 patients,
m o r et h a n4o ft h ef i r s t2 0p a t i e n t so rm o r et h a n2 0 %
of the further patients suffer from grade 4 toxicities
related to radiation therapy. A temporary discontinua-
tion of the study with a consecutive safety analysis will
be performed if ≥ 3 of 10 consecutive patients turn out
to be not grossly resectable during surgery.
Statistical considerations and sample size estimation
The primary endpoint of the trial is the local recurrence
rate after one year. The study is designed to demon-
strate that an additional radiation therapy consisting of
neoadjuvant short-term external beam radiation therapy
and intraoperative radiation therapy can improve the
local recurrence rate after one year. The local recur-
r e n c er a t ea f t e ro n ey e a ri nac o m p a r a b l ep a t i e n tp o p u -
lation treated with standard procedures (surgery
followed by adjuvant chemotherapy) was estimated to
be 30% according to the literature. The sample size cal-
culation was designed on the assumption to detect a
decrease of the local recurrence rate after one year by
20% (from 30% to 10%) with a power of 90%. Using the
two-sided binomial test with a level of significance of a
= 5%, the study requires 40 patients. Assuming a drop-
out rate of 15% of patients, who will not be available for
the evaluation of local recurrence after one year because
of death by distant disease progression or other reasons,
the total number of patients recruited for the trial will
be 46. Secondary endpoints are all of explorative nature
and reported using descriptive methods. Time to event
data (progression free survival, overall survival) will be
evaluated using the Kaplan-Meier-Method.
Biomarker
Even in the favourable patients group with primarily
resectable pancreatic cancer, long term survival is lim-
ited to about 15-20% of the patients due to high rates of
local and distant failures. Additional treatments like che-
motherapy or radiation therapy could improve the
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treatments can be accompanied by substantial side
effects leading to reduced quality of life. Therefore it
seems important to identify subsets of patients who are
more likely to profit from an additional treatment. To
identify predictors of outcome, blood and tissue samples
of each patient will be examined. Blood samples will be
taken before the first day, after the third and the fifth
day of neoadjuvant external beam radiation therapy,
before surgery and at discharge from the hospital stay
after surgery. Tissue samples will be taken during
surgery.
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